STAAR surgical swings to profit as revenue more than doubles on China growth
STAAR Surgical (NASDAQ:STAA) reported first-quarter net sales of $93.5 million, an 119.6% increase over the $42.6 million recorded in the first quarter of 2025.
The company’s performance was heavily influenced by a surge in demand for its EVO family of Implantable Collamer Lenses (EVO ICL).
Excluding China, net sales grew by 6% year-over-year to $46.1 million, highlighting the outsized role the Chinese market played in the quarter’s top-line beat.
Profitability metrics also saw a substantial uplift.
Gross margin expanded to 73.6%, up from 65.8% a year ago, reflecting higher production volumes and a favorable geographic product mix.
The company swung to a net income of $5.2 million, or $0.10 per diluted share, a stark contrast to the net loss of $54.2 million, or $1.10 per share, reported during the same quarter last year.
On an adjusted basis, EBITDA reached $24.4 million ($0.48 per diluted share), compared to an adjusted EBITDA loss of $26.3 million in the first quarter of 2025.
Management attributed the reversal to disciplined operational spending and the successful execution of commercial initiatives in key growth territories.
More from United States
Amazon Q3 revenue accelerates 12% to $201.9 billion as AWS growth accelerates
Intel Q3 revenue skyrockets 21% to $16.5B as data center sales surge
Merck raises FY profit outlook as Q3 revenue climbs 5% to $18.1B
Eli Lilly Q3 revenue surges 39% to $24.4 billion as guidance rises
Enterprise Products Q3 EBITDA jumps 16% to $2.8 billion
KBR Q3 revenue rises 5% to $2 billion as adjusted EBITDA grows 12%
